JERUSALEM, Israel , December 3, 2014 /PRNewswire/ --
Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a developer of oral drug delivery systems, today announced that it has received $5 million in connection with the definitive agreement with Guangxi Wuzhou Pharmaceutical Co., Ltd., a subsidiary of Guangxi Wuzhou Zhongheng Group Company Ltd (SHA:600252) previously reported on November 3, 2014 , for the purchase of 696,378 restricted shares of common stock for $7.18 per share, the closing price of Oramed's common stock on Friday, October 31, 2014 , in a private placement.
Venture, Inc. , a closed-end fund that has elected to be regulated as
a business development company (“BDC”) under the Investment Company Act
of 1940, as amended (“BDCA Venture” or the “Company”) (Nasdaq: BDCV),
announced today that it has launched a new initiative aimed at lowering
operating costs and ensuring that non-incentive advisory compensation is
more closely tied to investment performance.
Kayne Anderson Midstream/Energy Fund, Inc. (the “Fund”) (NYSE:KMF) today
provided a summary unaudited statement of assets and liabilities and
announced its net asset value and asset coverage ratios under the
Investment Company Act of 1940 (the “1940 Act”) as of October 31, 2014.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.